[1] 马树人.较大剂量阿托伐他汀对择期PCI术者心肌保护作用[J].东南大学学报(医学版),2011,30(6):901-904.
[2] 肖立运.盐酸替罗非班联合经皮冠状动脉介入治疗对急性心肌梗死干预相关性研究[J].现代中西医结合杂志,2016,25(17):1895-1897.
[3] 谢杏利,邹兵.抑郁患者心理状况及心理干预疗效分析[J].东南大学学报(医学版),2010,29(6):627-630.
[4] 张芳,李翠香,宋向芹,等.结构式心理护理对经皮冠脉介入治疗患者疾病不确定感及心血管不良事件的影响[J].中华现代护理杂志,2017,23(20):172-175.
[5] 杨宁,陈少伯,王玉萍,等.冠心病合并糖尿病患者经皮冠状动脉介入治疗术后焦虑及抑郁情绪药物干预的研究[J].中国慢性病预防与控制,2015,23(1):11-13.
[6] UEKI C,MIYATA H,MOTOMURA N,et al.Previous percutaneous coronary intervention does not increase adverse events after coronary artery bypass surgery[J].Ann Thorac Surg,2017,104(1):56-61.
[7] 赵东晖,宁俊霞,范谦,等.经皮冠状动脉介入治疗合并缺血性卒中患者发生不良事件的危险因素分析[J].内科急危重症杂志,2015,21(1):9-11.
[8] 王树源,黄家卓.血清总胆红素水平与ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术前梗死相关动脉血流及院内主要心脏不良事件的相关性研究[J].实用心脑肺血管病杂志,2016,24(3):11-14.
[9] VALLE J A,MCCOY L A,MADDOX T M,et al.Longitudinal risk of adverse events in patients with acute kidney injury after percutaneous coronary intervention:insights from the national cardiovascular data registry[J].Circ Cardiovasc Interv,2017,10(4):271-274.
[10] 史利锋,林平,陈巍,等.经皮冠状动脉介入治疗术后心脏不良事件与冠心病危险因素关系的研究进展[J].解放军护理杂志,2015,5(7):27-29.
[11] RURREN B,ROEST M,MCCLELLAN E A,et al.Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention[J].Thromb Haemost,2016,115(2):353-360.
[12] 首云锋,陈万,徐小华.替罗非班对急性心肌梗死患者急诊经皮冠状动脉介入治疗后主要心脏不良事件发生率的影响[J].国际心血管病杂志,2017,3(1):109.
[13] KWOK C S,KHAN M A,RAO S V,et al.Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events systematic review and meta-analysis[J].Circ Cardiovasc Interv,2015,8(4):261-264.
[14] 柳亚敏,刘乃丰.P2Y12基因多态性与PCI术后患者氯吡格雷反应变异性的关联分析[J].东南大学学报(医学版),2011,30(3):449-453.
[15] 郭凤云,张艺梅,张维,等.院后护理干预在急性心肌梗死直接经皮冠状动脉介入治疗患者中的应用[J].检验医学与临床,2015,3(6):743-744. |